Download
s40348-020-00101-9.pdf 687,05KB
WeightNameValue
1000 Titel
  • Osteogenesis imperfecta—pathophysiology and therapeutic options
1000 Autor/in
  1. Etich, Julia |
  2. Leßmeier, Lennart |
  3. Rehberg, Mirko |
  4. Sill, Helge |
  5. Zaucke, Frank |
  6. Netzer, Christian |
  7. Semler, Oliver |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-08-14
1000 Erschienen in
1000 Quellenangabe
  • 7(1):9
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s40348-020-00101-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427672/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Osteogenesis imperfecta (OI) is a rare congenital disease with a wide spectrum of severity characterized by skeletal deformity and increased bone fragility as well as additional, variable extraskeletal symptoms. Here, we present an overview of the genetic heterogeneity and pathophysiological background of OI as well as OI-related bone fragility disorders and highlight current therapeutic options.The most common form of OI is caused by mutations in the two collagen type I genes. Stop mutations usually lead to reduced collagen amount resulting in a mild phenotype, while missense mutations mainly provoke structural alterations in the collagen protein and entail a more severe phenotype. Numerous other causal genes have been identified during the last decade that are involved in collagen biosynthesis, modification and secretion, the differentiation and function of osteoblasts, and the maintenance of bone homeostasis.Management of patients with OI involves medical treatment by bisphosphonates as the most promising therapy to inhibit bone resorption and thereby facilitate bone formation. Surgical treatment ensures pain reduction and healing without an increase of deformities. Timely remobilization and regular strengthening of the muscles by physiotherapy are crucial to improve mobility, prevent muscle wasting and avoid bone resorption caused by immobilization. Identification of the pathomechanism for SERPINF1 mutations led to the development of a tailored mechanism-based therapy using denosumab, and unraveling further pathomechanisms will likely open new avenues for innovative treatment approaches.
1000 Sacherschließung
lokal Genetic heterogeneity
lokal Pathophysiology
lokal Therapy
lokal Mini Review
lokal Osteogenesis imperfecta
lokal Bisphosphonates
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RXRpY2gsIEp1bGlh|https://frl.publisso.de/adhoc/uri/TGXDn21laWVyLCBMZW5uYXJ0|https://frl.publisso.de/adhoc/uri/UmVoYmVyZywgTWlya28=|https://frl.publisso.de/adhoc/uri/U2lsbCwgSGVsZ2U=|https://frl.publisso.de/adhoc/uri/WmF1Y2tlLCBGcmFuaw==|https://frl.publisso.de/adhoc/uri/TmV0emVyLCBDaHJpc3RpYW4=|https://orcid.org/0000-0003-0029-7556
1000 Hinweis
  • DeepGreen-ID: fc5a2594e9384f93994cd9512ace7db5 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Osteogenesis imperfecta—pathophysiology and therapeutic options
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6472286.rdf
1000 Erstellt am 2023-11-18T19:24:06.160+0100
1000 Erstellt von 322
1000 beschreibt frl:6472286
1000 Zuletzt bearbeitet Fri Apr 05 12:46:00 CEST 2024
1000 Objekt bearb. Fri Apr 05 12:46:00 CEST 2024
1000 Vgl. frl:6472286
1000 Oai Id
  1. oai:frl.publisso.de:frl:6472286 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source